NAP
ANIK icon

New Amsterdam Partners’s Anika Therapeutics ANIK Stock Holding History

New Amsterdam Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-64,829
Closed -$3.76M – 114
2017
Q3 		$3.76M Sell
64,829
-707
-1% -$37K 0.79% 53
2017
Q2 		$3.23M Buy
65,536
+9,939
+18% +$458K 0.69% 58
2017
Q1 		$2.42M Sell
55,597
-81
-0.1% -$3.87K 0.57% 69
2016
Q4 		$2.73M Buy
+55,678
New +$2.57M 0.62% 61
2016
Q2 		– Sell
-108,260
Closed -$4.84M – 122
2016
Q1 		$4.84M Buy
+108,260
New +$4.39M 0.51% 59

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

New Amsterdam Partners's ANIK Position: Q4 2017 in Review

New Amsterdam Partners sold out of Anika Therapeutics (ANIK) in Q4 2017, closing a stake of 64,829 shares — an estimated $3.76M sold.

New Amsterdam Partners first reported a position in ANIK in Q1 2016 and held it in 5 quarters. The position peaked at $4.84M in Q1 2016. 172 funds tracked by Wall St. Rank hold ANIK as of Q4 2017.

  • New Amsterdam Partners reported no remaining Anika Therapeutics position as of Q4 2017 after selling out during the quarter.
  • New Amsterdam Partners sold 64,829 Anika Therapeutics shares in Q4 2017, an estimated $3.76M.
  • New Amsterdam Partners first reported a position in Anika Therapeutics in Q1 2016 and held it in 5 quarters.
  • New Amsterdam Partners's Anika Therapeutics position peaked at $4.84M in Q1 2016.
  • 172 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2017.

Based on New Amsterdam Partners's 13F filing for Q4 2017, filed 2 Feb 2018.